Mastocytosis and Hymenoptera venom allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 4, 2006, Pages 284-288

  Ruëff, Franziska ^a   Placzek, Marianne ^a   Przybilla, Bernhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Diagnosis; Efficacy; Hymenoptera venom allergy; Mastocytosis; Sensitization; Serum tryptase; Side effects; Venom immunotherapy

Indexed keywords

BEE VENOM; HYMENOPTERA VENOM; TRYPTASE; UNCLASSIFIED DRUG; VENOM; VESPID VENOM; ARTHROPOD VENOM;

ALLERGY; DEATH; FATALITY; HUMAN; HYMENOPTERA VENOM ALLERGY; IMMUNOTHERAPY; INSECT ALLERGY; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; SCREENING TEST; SKIN EXAMINATION; SYMPTOM; TREATMENT FAILURE; ANIMAL; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOLOGY;

ANIMALS; ARTHROPOD VENOMS; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; MASTOCYTOSIS;

EID: 33748456287     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000235903.10548.63     Document Type: Review

References (43)

1. Dubois AE. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004; 4:291-295.
2. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14:190-204.
3. Ludolph-Hauser D, Ruëff F, Fries C, et al. Constitutionally raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-362.
4. Haeberli G, Bronnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-1220.
5. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23:749-786.
6. Maurer M, Metz M. The status quo and quo vadis of mast cells. Exp Dermatol 2005; 14:923-929.
7. Pardanani A, Kimlinger TK, Reeder TL, et al. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003; 120:691-694.
8. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28:1319-1325.
9. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-625.
10. Hidvegi B, Nagy E, Szabo T, et al. Correlation between T-cell and mast cell activity in patients with chronic urticaria. Int Arch Allergy Immunol 2003; 132:177-182.
11. Dugas-Breit S, Schopf P, Dugas M, et al. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005; 3:343-347.
12. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43:1097-1105.
13. Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999; 141:1110-1112.
14. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96:5S-13S.
15. Florian S, Krauth MT, Simonitsch-Klupp I, et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136:273-280. This is a detailed case report on a test-negative patient with HVA and mastocytosis. Furthermore, the study contains a retrospective analysis of 40 patients with mastocytosis with respect to anaphylactic reactions.
16. Rosbotham JL, Malik NM, Syrris P, et al. Carter ND: lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999; 140:849-852.
17. Müller UR, Horat W, Wüthrich B, et al. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983; 72:685-689.
18. Oude Elberink JNG, de Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-154.
19. Bucher B, Simic P, Furrer J, Wüthrich B. Mastocytosis: an important differential diagnosis in anaphylactoid reaction to Hymenoptera sting. A case report and overview of clinical aspects, diagnosis and current therapy of mastocytosis. Schweiz Rundsch Med Prax 2000; 89:411-418.
20. Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273-276.
21. Reimers A, Müller U. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin Immunol Int J WAO Org 2005; 17 (SUPPL 1):69-70.
22. Ruëff F, Dugas-Breit S, Bauer C, et al. Diagnosis and treatment of Hymenoptera venom allergy in mastocytosis. [in German]. Allergo J 2005; 14:514-515.
23. Kors JW, Van Doormaal JJ, De Monchy JGR. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Internal Med 1993; 233:255-258.
24. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100:11-15.
25. Kränke B, Sturm G, Aberer W. Negative venom skin test results and mastocytosis. J Allergy Clin Immunol 2004; 113:180-181.
26. Price LA, Safko M. Bee venom allergy in a patient with urticaria pigmentosa. J Allergy Clin Immunol 1987; 79:407-409.
27. Engler RJM, Davis WS. Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. J Allergy Clin Immunol 1994; 94:556-559.
28. Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol 1997; 100:182-184.
29. Rieger-Ziegler V, Rieger E, Kränke B, Aberer W. Hymenoptera venom allergy: time course of specific IgE concentrations during the first weeks after a sting. Int Arch Allergy Immunol 1999; 120:166-168.
30. Golden DB, Kagey-Sobotka A, Norman PS, et al. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001; 107:897-901.
31. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027-1032.
32. Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-1010.
33. Ruëff F, Bauer C, Albert K, Przybilla B. Mastocytosis is a stronger risk factor for treatment failure of Hymenoptera venom immunotherapy than elevated baseline serum tryptase. Allergy Clin Immunol Int J WAO Org 2005; 17(Suppl 1):69.
34. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-535.
35. Przybilla B, Müller U, Jarisch R, Ruëff F. Elevated baseline serum tryptase concentration or mastocytosis as risk factor for Hymenoptera venum allergy. Guidelines of the German Association of Allergology and Clinical Immunology. [in German]. Allergo J 2004; 3:440-442.
36. Ruëff F, Przybilla B, Muller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Allergy 1996; 51:216-225.
37. Golden DBK, Addison BI, Gadde J, et al. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989; 84:162-167.
38. Haugaard L, Nørregaard OFH, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699-702.
39. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339-348.
40. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-658.
41. Van Halteren HK, van der Linden P-WG, Burgers JA, Bartelink AKM. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100:767-770.
42. Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702-709.
43. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000; 105:385-390.